Idrees Raza

Mr. Idrees Raza

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ASAamir Sohail
Aamir Sohail
HFHajra Fayyaz
Hajra Fayyaz
HMHamza Muneer
Hamza Muneer
IRIdrees Raza
Idrees Raza
MIMuhammad Ikram
Muhammad Ikram
IUImran Ullah
Imran Ullah
Type 2 diabetes mellitus (T2DM) is one of the most common forms of diabetes. We are living in the middle of a global diabetes epidemic. Emerging pieces of evidence are suggesting the increased expression of protein tyrosine phosphatase 1B (PTP1B) in the pancreas and adipose tissues during T2DM. The negative regulation of the insulin signaling pathway by PTP1B helps the researchers to consider it as a potential therapeutic target for the treatment of insulin resistance and its associated complications. From the literature, we found that compound 5,7‐dihydroxy‐3,6‐dimethoxy‐2‐(4‐methoxy‐3‐(3‐methyl‐2‐enyl)phenyl)‐4H‐chromen‐4‐one (Viscosol) extracted from Dodonaea viscosa can inhibit PTP1B in vitro. Therefore, in this study, we aimed to evaluate the antidiabetic effect of this compound in a high‐fat diet (HFD) and low‐dose streptozotocin‐ (STZ‐) induced T2DM mouse model. For this purpose, T2DM was induced in C57BL/6 male mice by using an already established protocol with minor modification. The compound‐treated T2DM mice showed improvements in biochemical parameters, i.e., decrease in the fasting blood glucose level, increased body weight, improved liver profile, and reduction in oxidative stress. Furthermore, to elucidate the inhibition of PTP1B, the expression level of PTP1B was also measured at mRNA and protein levels by real‐time PCR and western blot, respectively. Additionally, downstream targets (INSR, IRS1, PI3K, and GLUT4) were examined for confirming the inhibitory effect of PTP1B. Our results suggest that the compound can specifically inhibit PTP1B in vivo and might have the ability to improve insulin resistance and insulin secretion. Based on our experiment, we can confidently state that this compound can be a new PTP1B drug candidate for the treatment of T2DM in the coming future.

1 January 2024 in International Journal of Endocrinology
Verified
Journal Article
Open access
IRIdrees Raza
Idrees Raza
ASAamir Sohail
Aamir Sohail
HMHamza Muneer
Hamza Muneer
HFHajra Fayyaz
Hajra Fayyaz
ZUZia Uddin
Zia Uddin
IUImran Ullah
Imran Ullah
Type 2 diabetes mellitus (T2DM), a metabolic disorder, has the hallmarks of persistent hyperglycemia, insulin resistance, and dyslipidemia. Protein‐tyrosine phosphatase 1B (PTP1B) was found to be overexpressed in many tissues in the case of T2DM and involved in the negative regulation of insulin signaling. So, PTP1B inhibition can act as a therapeutic target for T2DM. Numerous studies claimed the anti‐inflammatory, hypoglycemic, hepatoprotective, and hypolipidemic activities of Dodonaea viscosa. Previously, we generated the high‐fat diet (HFD)‐low dose streptozotocin (STZ)–induced diabetic male mice model and treated it with a PTP1B inhibitor (5, 7‐dihydroxy‐3, 6‐dimethoxy‐2‐ (4‐methoxy‐3‐ (3‐methyl‐2‐enyl) phenyl)‐4H‐chromen‐4‐one), isolated from Dodonaea viscosa. In the current study, we aimed to investigate the De novo lipogenesis, adipocyte differentiation, augmentation of lipoproteins clearance, fatty acid uptake, antilipolysis activity, and hepatic steatosis of PTP1B inhibition in adipose and liver tissues of the HFD‐STZ–induced diabetic mice model. We found the retrieval of normal morphology of adipocytes and hepatocytes in the compound‐treated group. The biochemical parameters showed the gradual reduction of LDL, VLDL, TC, and TG in the serum of the compound‐treated group. To further test our hypothesis, real‐time PCR was performed, and data revealed the reduction of PTP1B and other inflammatory markers in both tissues, showing enhanced expression of insulin signaling markers (INSR, IRS1, IRS2, and PI3K). Our compound upregulated the adipogenic (PPARγ), lipogenic (SREBP1c, FAS, ACC, and DGAT2), lipoprotein clearance (LPL, LDLR, and VLDLR), fatty acid uptake (CD36 and FATP1), and lipid droplet forming (FSP27 and perilipin‐1) markers expressions in adipocytes and downregulated in hepatocytes. Furthermore, we found elevated cholesterol efflux (in adipose and liver) and decreased lipolysis in adipocytes and elevated in hepatocytes. Hence, we can conclude that our compound protects the adipocytes from abrupt lipolysis and stimulates adipocyte differentiation. In addition, it plays a hepatic protective role by shifting clearance and uptake of lipoproteins and fatty acids to the peripheral tissues and retrieving the fatty liver condition.

11 July 2025
Verified
Book Chapter
Open access
PDF file
MAMuhammad Asim
Muhammad Asim
AAAleena Altaf
Aleena Altaf
ASAamir Sohail
Aamir Sohail
MAMaimoona Arshad
Maimoona Arshad
FNFaiza Noreen
Faiza Noreen
IUImran Ullah
Imran Ullah
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), involves excessive fat buildup in liver cells and is closely linked to insulin resistance, type 2 diabetes mellitus (T2DM), and dyslipidemia. This chapter discusses MASLD pathophysiology, focusing on disrupted lipid metabolism, inflammation, and the key role of protein tyrosine phosphatase 1B (PTP1B) in insulin signaling and metabolic balance. The high-fat diet (HFD) plus low-dose streptozotocin (STZ) mouse model mimics human T2DM and MASLD, showing hyperglycemia, lipid abnormalities, and liver fat accumulation. Viscosol, a flavonoid from Dodonaea viscosa, shows strong therapeutic potential as a PTP1B inhibitor. Given at 33 mg/kg intraperitoneally for 7 days, Viscosol improved insulin sensitivity by increasing insulin receptor (INSR), IRS1/2, PI3K, and AKT expression, and regulated lipid metabolism genes (SREBP1c, FAS, PPARγ). It lowered serum low density lipoprotein (LDL), very low-density lipoprotein (VLDL), and total cholesterol. Histology showed less liver fat, reduced fibrosis markers (α-SMA, TGF-β1), and decreased inflammation. Viscosol also boosted cholesterol efflux via ABCA1 and ApoA1 and lowered inflammatory cytokines (TNF-α, IL-6) and the oxidative stress marker FOXO1, restoring metabolic health. These results suggest Viscosol as a promising natural agent targeting PTP1B to treat insulin resistance, dyslipidemia, and hepatic steatosis in MASLD and T2DM. Further clinical studies are needed to confirm these effects in humans.